8:15 am Digital Networking Room Opens
8:45 am Chair’s Opening Remarks
Cutting-Edge Claudin Development: Showcasing Development of Novel Claudin Therapies Revolutionizing Oncology
9:00 am Zolbetuximab: Clinical Development of Claudin 18.2 Monoclonal Antibodies
Synopsis
- Exploring Zolbetuximab, a monoclonal antibody targeting claudin 18.2, and its application in treating metastatic gastric cancer
- Reviewing a detailed presentation on clinical trial outcomes, including efficacy, safety, and the impact on progression-free survival and overall survival rates
- Integrating Zolbetuximab into standard treatment regimens and its potential for combination with other therapeutic modalities
9:30 am Preclinical Showcase of XmAb541 in Claudin 6-Targeted Bispecific Antibody Therapy
Synopsis
• Showcasing Xencor’s XmAb541, a CLDN6 x CD3 bispecific antibody, designed to engage T cells and selectively kill claudin 6 expressing tumor cells while sparing normal tissues
• Uncovering preclinical data, focusing on safety, tolerability, and preliminary efficacy against ovarian cancer and other solid tumors
• Outlining future development plans, including combination strategies with other immunotherapies and expansion into additional CLDN6-positive cancer types
10:00 am Morning Break & Networking
Clinical Modality Advancements & Biological Insights in Claudin-Targeted Cancer Therapies
11:00 am Panel Discussion: Clinical Advancements in Claudin-Targeted ADCs, Bispecifics, & CAR-T Therapies
Synopsis
- Deep diving into the latest advancements and clinical outcomes of ADCs targeting Claudin 18.2 and Claudin 6, with a focus on engineering, payload optimization, and toxicity management specific to claudin targets
- Examining the role and efficacy of bispecific antibodies in enhancing the immune response against claudin-expressing tumors, supported by insights from preclinical and clinical data
- Analyzing the development, challenges, and clinical trial results of CAR-T therapies for claudin-targeted treatments, emphasizing construct design, manufacturing hurdles, and strategies for managing associated toxicities
11:45 am Understanding the Synergistic Potential of Combining Claudin 18.2-Targeted Therapies with Immunotherapies
Synopsis
- Examining the rationale for combining Claudin 18.2-targeted therapies with immunotherapies, such as checkpoint inhibitors, to enhance anti-tumour immune responses
- Exploring preclinical and clinical data supporting combination strategies, focusing on the synergistic effects and improved therapeutic outcomes
- Reviewing the impact of combination therapies on efficacy and safety profiles, including strategies to manage immune-related adverse events
12:15 pm Addressing & Mitigating Gastrointestinal Toxicity in Claudin-Targeted Cancer Treatments
Synopsis
- Investigating the gastrointestinal toxicity associated with claudin-targeted therapies, including mechanisms of toxicity and patient case studies
- Understanding strategies for managing and mitigating GI toxicity, such as dose adjustments, supportive care measures, and novel therapeutic approaches
- Exploring clinical trial designs aimed at reducing treatment-related GI toxicity, including the use of predictive biomarkers and early intervention strategies
12:45 pm Lunch & Networking
Exploring Innovations & Applications in Claudin 6-Targeted Cancer Therapies
1:45 pm Engineering Next-Generation Claudin 6 T-Cell Engagers for Enhanced Specificity & Efficacy
Synopsis
- Navigating the challenges and strategies in developing Claudin 6 T-Cell engagers with high selectivity, minimizing off-target effects on normal tissues
- Exploring the 2+1 format for Claudin 6 T-Cell engagers, designed to enhance tumor selectivity and reduce toxicity
- Reviewing preclinical data demonstrating the potential advantages of Claudin 6 T-Cell engagers in treating germ cell cancers, focusing on efficacy and safety outcomes
2:15 pm Development & Application of Claudin 6-Targeted Therapies in Ovarian, Testicular, & Endometrial Cancers
Synopsis
- Focusing on Claudin 6 expression in ovarian, testicular, and endometrial cancers and the potential for targeted therapies in these indications
- Uncovering the development and clinical potential of ADCs targeting Claudin 6, including preclinical efficacy and safety data
- Highlighting the safety profile and patient selection criteria for Claudin 6-targeted therapies, including strategies to minimize off-target effects